Triple negative breast cancer (TNBC) is a subtype of breast cancer that comprises 15-20% of all breast cancer cases and is characterized by aggressive clinical features.
Breast Cancer Editorial TOUCH MEDICAL MEDIA Triple negative breast cancer (TNBC) is a subtype of breast cancer that comprises 15-20% of all breast cancer cases and is characterized by aggressive clinical features. 1 Compared to estrogen receptor (ER)-positive cancers, it carries an increased risk for relapse within five years of diagnosis, increased propensity for spread to viscera like lungs and brain, and a lower incidence for bony metastases. TNBC is more common in younger women (<50 years old), African Americans, and those with BRCA1 germline mutations. The authors concluded the results support the use of platinum agents in neoadjuvant regimens for TNBC. Though additional subset analysis of TNBC patients with and without BRCA germline mutations suggested that DFS benefit was higher in those with wild-type BRCA status, these data should be considered hypothesis generating as the number of women with BRCA mutations was small (n=50) and this finding conflicts with previous studies that found platinum compounds were not active in BRCA wild-type patients.
Similarly, the CALGB 40603 study reported statistically significant higher rates of pCR in TNBC who received neoadjuvant platinum-based chemotherapy. 3 In contrast, however, the secondary endpoints of event-free survival (EFS) and OS presented at SABCS 2015 showed that the presence of pCR predicted improved EFS and OS, regardless of chemotherapy arm. 4 The authors acknowledged the study was underpowered to detect a In the setting of neoadjuvant chemotherapy, the approach to locoregional treatment is not modified based on response but instead is recommended based on pre-treatment characteristics such as tumor size and nodal involvement. 6 Local treatment options include breast-conserving therapy (BCT), defined as breast conserving surgery followed by radiation therapy (RT), or alternatively, mastectomy, with or without post-mastectomy radiation therapy (PMRT). Though the concern for higher locoregional recurrence (LRR) may indicate the need for more aggressive locoregional treatment (i.e. mastectomy), patients with basal-like TNBC undergoing mastectomy also remain at higher risk for LRR. 7 Hence, TNBC is not a contraindication for breast conservation therapy, because the increased LRR risks (relative to luminal subtypes) appear to be irrespective of whether the patient has mastectomy or breast conservation. 
